A significant study conducted in Denmark has found that a minimally invasive procedure known as ablation is as effective as traditional surgery for treating small kidney cancers, specifically T1a renal cell carcinoma. The study tracked nearly 1,900 patients over a period of almost ten years. Results were published in the journal Radiology, which is affiliated with the Radiological Society of North America.
The research highlights an increasing challenge in the healthcare system as incidental findings of this type of cancer rise due to routine imaging. Lead author Iben Lyskjær, Ph.D., M.Sc., an associate professor at Aarhus University and Aarhus Hospital, noted the pressing need for better risk stratification and treatment options. “While early detection improves outcomes, it also raises the need for improved management approaches,” she stated.
Minimally Invasive Approach Gaining Ground
Historically, surgical tumor resection has been the standard treatment for stage T1a renal cell carcinoma. However, ablation, which uses extreme heat (radiofrequency ablation) or cold (cryoablation) to destroy tumors, is gaining traction as a viable alternative. Since its introduction in Denmark in 2006, the use of ablation has steadily increased.
Dr. Lyskjær’s team conducted a nationwide registry-based cohort study of Danish adults diagnosed with T1a renal cell carcinoma between January 2013 and December 2021. The study compared outcomes for patients treated with ablation versus those who underwent surgical resection. Among the 1,862 patients included in the study, the median age was 64, and the cohort consisted of 1,305 men.
Participants were divided into three groups: the ablation group (540 patients), the resection group (1,002 patients), and the nephrectomy group (320 patients). In the ablation group, 42 patients received radiofrequency ablation, while the rest underwent cryoablation.
Findings Show Comparable Effectiveness
The study’s findings revealed no significant difference in the risk of cancer progression between the ablation and resection groups. While local recurrence rates were somewhat higher in the ablation group (2.41%) compared to the resection (1.20%) and nephrectomy (0%) groups, Dr. Lyskjær emphasized that recurrent tumors can often be effectively treated with either another ablation or surgery. Notably, patients who experienced local recurrences did not exhibit worse overall survival rates.
Additionally, the study indicated that distant metastasis occurred more frequently in patients who underwent nephrectomy (4.38%) compared to those treated with resection (1.90%) and ablation (1.67%). Patients who had ablation benefited from shorter hospital stays, with most being discharged on the same day as their procedure. They also had fewer hospital visits within the following 30 days, suggesting a lower incidence of complications.
“Our study demonstrated that the overall progression rates were low across all treatment modalities, supporting the effectiveness of both ablation and resection for T1a renal cell carcinoma,” Dr. Lyskjær concluded.
Despite the promising results, there remains uncertainty regarding whether incidental tumors would eventually develop into more aggressive cancers. Dr. Lyskjær advocates for a broader consideration of minimally invasive techniques, stating, “The best choice depends not only on the patient’s characteristics but also on their preferences. We should present patients with data and involve them in the decision-making process.”
As healthcare systems worldwide grapple with the implications of rising incidental diagnoses, findings such as these could reshape treatment paradigms for kidney cancer, prioritizing patient-centered approaches and minimizing invasive procedures.
